Ki-67 Antibody(DA076)

Description

Ki-67 is an antibody designed to target Ki-67 antigen-a nuclear protein encoded by the MKI67 gene whose presence correlates with G1, S, G2, and the mitotic phases of the cell cycle.1 Ki-67’s presence during cellular division makes it an excellent target for labeling rapidly growing malignancies.2 Given that its presence correlates with cell proliferation, the immunohistochemical labeling of Ki-67 antigen may be useful in characterizing a lesion’s growth fraction. It has been demonstrated that identifying this antigen by IHC is useful in characterizing lesions of the breast, lymphoid cells, astrocytes, and uterus.3-9 — Références — 1. Scholzen T, et al. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000; 182(3):311-22. 2. Sun X, et al. Ki-67: more than a proliferation marker. Chromosoma. 2018; 127(2):175-186. 3. Abd-Elazeem MA, et al. Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression. Annals of Diagnostic Pathology 2015; 19:37-42. 4. Inwald EC, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat. 2013; 139(2):539-552. 5. Ning J, et al. The impact of Ki-67 in the context of multidisciplinary care in primary inflammatory breast cancer. J Cancer. 2019; 10(12):2635-2642. 6. Broyde A, et al. Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma. Am J Hematol. 2009; 84(6):338-43. 7. Chuang SS, et al. Histopathology and immunohistochemistry in distinguishing Burkitt lymphoma from diffuse large B-cell lymphoma with very high proliferation index and with or without a starry-sky pattern: a comparative study with EBER and FISH. Am J Clin Path 2007 128(4):558-64. 8. Shivaprasad NV, et al. Ki-67 immunostaining in astrocytomas: Association with histopathological grade- A South Indian Study. J Neurosci Rural Pract. 2016 7(4):510-514. 9. Mayerhofer K, et al. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS). Acta Obstet Gynecol Scand. 2004; 83(11):1085-8.

Caractéristiques

Type

Recombinant monoclonal rabbit antibody

Clone

DA076

Isotype

Rabbit

Réactivité

Synthetic peptide from human Ki67

Localisation

Nucleus

Usage prévu

IHC (FFPE)